Roche is actively engaging with policy makers in Malaysia to achieve broad and rapid access for people with SMA Roche Malaysia announced that the National Pharmaceutical Regulatory Agency (NPRA) in Malaysia has approved Evrysdi™ (risdiplam) for the treatment of spinal muscular atrophy (SMA), a rare disease affecting patients two months of age and older. SMA is one of the genetic causes of death in infants. 5q SMA is one form of the disease [1] . The condition causes muscle weakness and progressive loss of movement and significant unmet need remains, particularly in adults living with this condition. "Children with SMA may start showing symptoms as early as the first few days of life and lose muscle strength over time, so early treatment is crucial before the weakness begins. While the age of onset and range and severity of symptoms varies from each individual, the physical and emotional challenges from SMA impacts the entire family," said Dr Ch'ng Gaik Siew, Paediatrician
